Lexaria Bioscience
LEXX
28 hedge funds and large institutions have $5.72M invested in Lexaria Bioscience in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
77% more capital invested
Capital invested by funds: $3.23M → $5.72M (+$2.49M)
12% more funds holding
Funds holding: 25 → 28 (+3)
0.49% more ownership
Funds ownership: 0.47% → 0.96% (+0.49%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.06M |
| 2 |
G
GenTrust
Miami,
Florida
|
+$180K |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$121K |
| 4 |
BlackRock
New York
|
+$77.8K |
| 5 |
Renaissance Technologies
New York
|
+$68.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$77K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$57.6K |
| 3 |
Morgan Stanley
New York
|
-$1.13K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$450 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AF
26
Allworth Financial
Folsom,
California
| $243 | – | – | – |
|
|
GCM
27
Gables Capital Management
Miami,
Florida
| $36 | – | – | – |
|
28
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $36 | – | – | – |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$57.6K | -1,057 | Closed |
|
LEXX Hedge Fund Activity: Q2 2024 in Review
28 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q2 2024, worth a combined $5.72M — up 77% from $3.23M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LEXX positions and 1 closed out — a net gain of 3 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.06M. The largest seller was ADAR1 Capital Management, cutting an estimated $77K.
- 28 institutional investors held Lexaria Bioscience (LEXX) as of Q2 2024, up from 25 in Q1 2024.
- Funds reported $5.72M of Lexaria Bioscience stock for Q2 2024, up 77% quarter-over-quarter.
- 4 funds opened new Lexaria Bioscience positions in Q2 2024 and 1 closed out, a net change of +3 holders.
- The largest Lexaria Bioscience buyer in Q2 2024 was Armistice Capital, an estimated $3.06M added.
- The largest Lexaria Bioscience seller in Q2 2024 was ADAR1 Capital Management, an estimated $77K sold.
Based on aggregated 13F filings for Q2 2024.